Eigenverlag/Self

Abstract:
Study, July 2018
IP/G/STOA/FWC/2013-001/LOT5/C2
Additive bio-manufacturing (bio-AM) is defined here as the use of 3D printing for medical purposes or non-therapeutic “human enhancement”, whether they involve the production of biological material or not. It includes any application for rehabilitating, supporting or augmenting biological functionality. The impacts of bio-AM are uncertain, and it is not clear which actions may be required to foster responsible development of the technology.
This study responds to these gaps in our knowledge by describing the state of the art and future development prospects, analysing their wide-ranging impacts - including social, ethical and economic aspects - and identifying key policy challenges along with options to respond to them. Key challenges are to avoid an incoherent, piecemeal adaptation of regulatory frameworks, to support responsible development that improves citizens’ lives, and to foster public participation and citizen-driven innovation. The European RRI approach could provide a useful platform for responding to these challenges, emphasising inclusiveness and co-creation by a wide variety of stakeholder groups, including public participation.
Authors: Arianna Ferrari, Martina Baumann, Christopher Coenen, Daniel Frank, Leonhard Hennen, António Moniz (KIT/ITAS); Helge Torgersen, Jan Torgersen (ITA/OEAW); Lisa van Bodegom, Freija van Duijne, Ingrid Geesink, Barend van der Meulen (Rathenau Institute); Emilio Mordini (RT); Karen Riisgaard, Rasmus Øjvind Nielsen (DBT Foundation).
Published by STOA (STOA@ep.europa.eu); Manuscript completed in July 2018
Brussels, (c) European Union, 2018